Navigation Links
Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
Date:11/8/2007

(now Biogen Idec). Marty was also a co-founder and Board member of Eyetech Pharmaceuticals.

"Marty's experience in working with top management to successfully finance and build emerging biopharmaceutical companies is an important addition to our team as we drive our lead product candidate toward late stage clinical development and commercialization," said Dr. Kirn.

About Jennerex

Jennerex Biotherapeutics is a clinical stage biotherapeutics company working to create, develop and commercialize first-in-class cancer products. Our products are engineered viruses that have been modified to be safe and effective against various forms of cancer. Jennerex products kill cancer by targeting, attacking and eradicating cancer cells. Our lead product candidate, JX-594, has demonstrated clear anti-cancer effects in a Phase 1 study in patients with late-stage liver cancer. Jennerex has initiated a Phase 2a clinical trial in the U.S., for liver cancer and is currently enrolling a Phase 2a clinical trial at several sites in the U.S. for metastatic melanoma. Jennerex is also planning a Phase 1 study with IV administration focusing on lung cancer and melanoma.

For more information about Jennerex, please visit http://www.jennerex.com.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... In 2013, Lawrence Livermore National ... Security LLC (LLNS), was awarded more than ... laser system for the European Union's Extreme Light ... the Czech Republic. , When commissioned to its ... " High repetition-rate Advanced Petawatt Laser System " ...
(Date:8/27/2014)... 27, 2014 Reportlinker.com announces that a ... catalogue: Global Chelating Agents Market 2014-2018 ... About Chelating Agent A chelating agent is a ... metal ions, thereby forming a metal-ion complex. It ... on chemical processes, formulations, and the environment by ...
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 ... of Guggenheim Partners, today announced the hiring of veteran ... and senior equity analyst. Mr. Butler will focus on ... brings our team a wealth of experience and a ... Dante Ferrarie , Senior Managing Director and Head of ...
(Date:8/27/2014)... , Aug. 27, 2014  ARCH Venture ... firms investing in the development of seed and ... eighth venture fund closed with more than $400 ... its $250 million subscription target by more than ... VIII shows the strength and potential of our ...
Breaking Biology Technology:LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3
... 28, 2011 Arteriocyte®, a leading clinical stage ... Hopkinton, Massachusetts that develops proprietary stem cell and ... the Food and Drug Administration (FDA) to initiate ... MAR01™ technology in the treatment of Critical Limb ...
... in Spanish and French . , WALNUT ... this fibrous diet consisting mainly of the tough to degrade plant ... to most animals, ruminants manage to extract all they need to ... the cow, or rather the network of organisms working unseen in ...
... of gold nanoparticles and viral particles, woven together and ... a distinctive mix of hard, metallic nanoparticles and ... very stuff of life, DNA marks a remarkable ... materials to create infinitesimal devices. The research, done ...
Cached Biology Technology:Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial 2Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial 3How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 2How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 3How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 4How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 5A mix of tiny gold and viral particles -- and the DNA ties that bind them 2
(Date:8/28/2014)... 2014 Dyslexia, the most commonly diagnosed learning ... reading disability that occurs when the regions of ... normally. , The use of non-invasive functional neuroimaging ... disrupted in dyslexia. However, most prior work has ... regions, leaving a gap in our understanding of ...
(Date:8/28/2014)... Washington, Oregon, northern California, and Alaska totaled 515 million ... 2014, an increase of more than 10 percent compared ... Service,s Pacific Northwest Research Station reported today. During this ... percent to 247 million board feet. , The total ... 5 percent to $390 million in the same quarter, ...
(Date:8/27/2014)... FREMONT, Calif. , Aug. 27, 2014  WaferGen ... completed its previously announced underwritten public offering of units ... $10,000 per unit for gross proceeds of $20 million, ... expenses payable by the Company.  The shares and warrants ... Each unit sold in the offering consists ...
Breaking Biology News(10 mins):Dyslexic readers have disrupted network connections in the brain 2West coast log exports up, lumber exports down in second quarter of 2014 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3
... N.C. In a finding that confirms what many ... younger women who undergo hysterectomies face a nearly two-fold ... published in the December issue of the journal ... track over time the actual hormonal impact of woman ...
... November 14, 2011 The possibility that functional, ... cells, such as embryonic stem cells (ESCs) and induced ... challenges of stem cell research, but is also one ... regenerative medicine. Developmental biology has played a central role ...
... CLEVELAND -- An estimated 300,000 people in North ... a progressive loss of motor control. Patients with generalized ... uncontrolled twisting and turning in awkward, sometimes painful postures. ... the disorder can have a devastating impact on quality ...
Cached Biology News:Hysterectomy increases risk for earlier menopause among younger women 2Self-organized pituitary-like tissue from mouse ES cells 2Self-organized pituitary-like tissue from mouse ES cells 3Self-organized pituitary-like tissue from mouse ES cells 4University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging 2University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging 3
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Assay Diluent 500 mls...
Biology Products: